{'52WeekChange': -0.48801744,
 'SandP52WeekChange': None,
 'address1': '9708 Medical Center Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.47,
 'askSize': 3100,
 'averageDailyVolume10Day': 779737,
 'averageVolume': 780046,
 'averageVolume10days': 779737,
 'beta': 2.532212,
 'beta3Year': None,
 'bid': 4.46,
 'bidSize': 3000,
 'bookValue': 3.407,
 'category': None,
 'circulatingSupply': None,
 'city': 'Rockville',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.79,
 'dayLow': 4.38,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.803,
 'enterpriseToRevenue': 4.825,
 'enterpriseValue': 43423428,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '301-738-2137',
 'fiftyDayAverage': 3.6648571,
 'fiftyTwoWeekHigh': 9.53,
 'fiftyTwoWeekLow': 1.82,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 19745269,
 'forwardEps': -1.64,
 'forwardPE': -2.7256095,
 'fromCurrency': None,
 'fullTimeEmployees': 57,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.02242,
 'heldPercentInstitutions': 0.94718003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/glycomimetics.com',
 'longBusinessSummary': 'GlycoMimetics, Inc., a clinical-stage biotechnology '
                        'company, focuses on the discovery and development of '
                        'novel glycomimetic drugs to address unmet medical '
                        'needs resulting from diseases in the United States. '
                        "The company's advanced drug candidate, rivipansel, is "
                        'a pan-selectin antagonist, which is developed for the '
                        'treatment of vaso-occlusive crisis in sickle cell '
                        'disease and is in a Phase III clinical trial, '
                        'conducted by its strategic collaboration with Pfizer '
                        'Inc. It is also developing uproleselan, an E-selectin '
                        'antagonist that is evaluated in a Phase I/II clinical '
                        'trial as a potential treatment for acute myeloid '
                        'leukemia (AML), as well as Phase III trial to treat '
                        'relapsed/refractory AML. In addition, the company '
                        'offers GMI-1359 that has completed Phase I clinical '
                        'trial to target E-selectin and a chemokine receptor '
                        'for various tumor types. Further, it is developing '
                        'various other programs, including GMI-1687, an '
                        'antagonist of E-selectin; and Galectin-3, a '
                        'carbohydrate-binding protein. The company has a '
                        'cooperative research and development agreement with '
                        'the National Cancer Institute. GlycoMimetics, Inc. '
                        'was founded in 2003 and is headquartered in '
                        'Rockville, Maryland.',
 'longName': 'GlycoMimetics, Inc.',
 'market': 'us_market',
 'marketCap': 194816000,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_5703481',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -51470616,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.67,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '240-243-1201',
 'previousClose': 4.7,
 'priceHint': 4,
 'priceToBook': 1.3120046,
 'priceToSalesTrailing12Months': 21.646223,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.79,
 'regularMarketDayLow': 4.38,
 'regularMarketOpen': 4.67,
 'regularMarketPreviousClose': 4.7,
 'regularMarketPrice': 4.67,
 'regularMarketVolume': 583169,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 43583000,
 'sharesPercentSharesOut': 0.064,
 'sharesShort': 2788778,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2682415,
 'shortName': 'GlycoMimetics, Inc.',
 'shortPercentOfFloat': 0.1308,
 'shortRatio': 2.06,
 'startDate': None,
 'state': 'MD',
 'strikePrice': None,
 'symbol': 'GLYC',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.187,
 'twoHundredDayAverage': 3.3971224,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'efe04473-e4ee-3464-8e89-48cc4b8490b8',
 'volume': 583169,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.glycomimetics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '20850'}